Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026)
Catheter Precision (VTAK) posted quarterly Current Deferred Revenue of $126000.0 for Q1 2026, down 92.95% quarter-over-quarter from $1.8 million in Q2 2021.
Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Catheter Precision (VTAK) has reported Current Deferred Revenue for 6 consecutive years, with $126000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $126000.0; the TTM figure through Mar 2026 stood at $126000.0 (changed N/A YoY), while the FY2020 annual figure was $2.5 million, down 24.24% from the prior year.
- Current Deferred Revenue fell to $126000.0 in Q1 2026 per VTAK's latest filing, from $1.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $126000.0 in Q1 2026 and bottomed at $126000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Catheter Precision | 564,834.50 | -1.27 Mn | 98,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126,000.00 |
| Jun 30, 2021 | 1.79 Mn |
| Mar 31, 2021 | 1.78 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 1.73 Mn |
| Jun 30, 2020 | 1.86 Mn |
| Mar 31, 2020 | 1.96 Mn |
| Dec 31, 2019 | 3.30 Mn |
| Sep 30, 2019 | 1.92 Mn |
| Jun 30, 2019 | 2.04 Mn |
| Mar 31, 2019 | 1.95 Mn |
| Dec 31, 2018 | 1.72 Mn |
| Sep 30, 2018 | 1.75 Mn |
| Dec 31, 2017 | 1.71 Mn |